Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Expression of a single ICAMâ1 isoform on T cells is sufficient for development of experimental autoimmune encephalomyelitis.
Patterns of Objective and Subjective Burden of Informal Caregivers in Multiple Sclerosis.
Astrocytic A20 ameliorates experimental autoimmune encephalomyelitis by inhibiting NF-κB- and STAT1-dependent chemokine production in astrocytes.
Small Molecule Inhibitor of Antigen Binding and Presentation by HLA-DR2b as a Therapeutic Strategy for the Treatment of Multiple Sclerosis.
Systematic network lesioning reveals the core white matter scaffold of the human brain.
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.
Experimental autoimmune encephalomyelitis and age-related correlations of NADPH oxidase, MMP-9, and cell adhesion molecules: The increased disease severity and blood-brain barrier permeability in middle-aged mice.
Multiple sclerosis and neurofibromatosis type 1: report of seven patients from Iran.
[Intravenous immunoglobulin in treatment of autoimmune neurological diseases in children].
The management of multiple sclerosis by reference centers in south of Italy: a 2011 survey on health demands and needs in Campania region.
The effect of inflammation and its reduction on brain plasticity in multiple sclerosis: MRI evidence.
Resveratrol Promotes Remyelination in Cuprizone Model of Multiple Sclerosis: Biochemical and Histological Study.
Possible Relations Between Epstein-Barr Virus Past Infection and Classic Multiple Sclerosis in Guilan, Iran.
Urodynamics in the Evaluation of the Patient with Multiple Sclerosis: When Are They Helpful and How Do We Use Them?
Acute neuronal apoptosis in a rat model of multiple sclerosis.
Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant.
Dimethylfumarate Impairs Neutrophil Functions.
Intracerebroventricular injection of lipopolysaccharide increases gene expression of connexin32 gap junction in rat hippocampus.
Changes of brain resting state functional connectivity predict the persistence of cognitive rehabilitation effects in patients with multiple sclerosis.
Guwiyang Wurra-'Fire Mouse': a global gene knockout model for TSPO/PBR drug development, loss-of-function and mechanisms of compensation studies.
Treatment Costs and Patterns In Patients With Multiple Sclerosis Treated With Prolonged-Release Fampridine In Germany.
Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS.
Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis.
Successful antiviral treatment of chronic hepatitis C in patients with rare comorbidities. Two case-reports.
Presence of the HLADR13 allele among Mexican Mestizos suggests a protective factor against relapsing-remitting multiple sclerosis (RRMS).
Pages
« first
‹ previous
…
665
666
667
668
669
670
671
672
673
…
next ›
last »